NZ283988A

NZ283988A - Rapamycin hydroxyesters and medicaments

Info

Publication number: NZ283988A
Application number: NZ283988A
Authority: NZ
Inventors: Jerauld Stanley Skotnicki; Christina Louise Leone; Guy Alan Schiehser
Original assignee: American Home Prod
Priority date: 1994-04-18
Filing date: 1995-04-14
Publication date: 1998-07-28
Also published as: CY2008012I2; ATE537176T1; EP1266899A3; CA2187024A1; AU2247495A; ES2375730T3; CA2187024C; DE69529897T3; CN1149296A; PT1266899E; PT763039E; DE69529897T2; EP0763039B3; ES2191704T7; CY2378B1; SI1266899T1; HUT77410A; DK0763039T3; SI0763039T1; CZ284567B6

Abstract

A compound of structure (I) wherein R 1 and R 2 are each, independently, hydrogen or - CO(CR 3 R 4 ) b (CR 5 R 6 ) d CR 7 R 8 R 9 ; R 3 and R 4 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, trifluoromethyl, or -F; R 5 and R 6 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, -(CR 3 R 4 ) f OR 10 , -CF 3 , -F, or -CO 2 R 11 , or R 5 and R 6 may be taken together to form X or a cycloalkyl ring that is optionally mono-, di-, or tri-substituted with - (CR 3 R 4 ) f OR 10 ; R 7 is hydrogen, alkyl, alkenyl, alkynyl, -(CR 3 R 4 ) f OR 10 , -CF 3 , -F, or -CO 2 R 11 ; R 8 and R 9 are each, independently, hydrogen, alkyl, alkenyl, alkynyl, -(CR 3 R 4 ) f OR 10 , -CF 3 , -F, or -CO 2 R 11 , or R 8 and R 9 may be taken together to form X or a cycloalkyl ring that is optionally mono-, di-, or tri-substituted with -(CR 3 R 4 ) f OR 10 ; R 10 is hydrogen, alkyl, alkenyl, alkynyl, tri-(alkyl)silyl, tri-(alkyl)silylethyl, triphenylmethyl, benzyl, alkoxymethyl, tri-(alkyl)silylethoxymethyl, chloroethyl, or tetrahydropyranyl; R 11 is hydrogen, alkyl, alkenyl, alkynyl, or phenylalkyl; X is 5-(2,2-dialkyl)[1,3]dioxanyl, 5-(2,2-dicycloalkyl)[1,3]dioxanyl, 4-(2,2-dialkyl)[1,3]-dioxanyl, 4-(2,2-dicycloalkyl)[1,3]dioxanyl, 4-(2,2-dialkyl)[1,3]dioxalanyl, or 4-(2,2-dicycloalkyl)[1,3]dioxalanyl; b = 0-6; d = 0-6; and f = 0-6 with the proviso that R 1 and R 2 are both not hydrogen and further provided that either R 1 or R 2 contains at least one -(CR 3 R 4 ) f OR 10 , X, or -(CR 3 R 4 ) f OR 10 substituted cycloalkyl group, or a pharmaceutically acceptable salt thereof which is useful as an immunosuppressive, antiinflammatory, antifungal, antiproliferative, and antitumor agent.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number £83988 £ New Zealand No. 283988 International No. PCT/US95/04603 TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION Priority dates: 18.04.1994; Complete Specification Filed: 14.04.1995 Classification: (6) C07D498/18; A61K31/435 Publication date: 28 July 1998 Journal No.: 1430 Title of Invention: Rapamycin hydroxyesters, process for their preparation and pharmaceutical compositions containing them Name, address and nationality of applicant(s) as in international application form: AMERICAN HOME PRODUCTS CORPORATION, Five Giralda Farms, Madison, New Jersey 07940-0874, United States of America NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION WO 95/28406 PCTAJS9S/04603 <839 RAPAMYCIN HYDROXYESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BACKGROUND OF THE INVENTION This invention relates to hydroxyesters of rapamycin and their use in the manufacture of medicaments for inducing immunosuppression, and in the treatment of transplantation rejection, graft vs. host disease, autoimmune diseases, diseases of inflammation, adult T-cell leukemia/lymphoma, solid tumors, fungal infections, and hyperproliferative vascular disorders. Rapamycin is a macrocyclic triene antibiotic produced by Stremomvces hygroscopicus. which was found to have antifungal activity, particularly against Candida albicans, both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S.N. Sehgal e: al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Patent 3,929,992; and U.S. Patent 3,993,749]. Rapamycin alone (U.S. Patent 4,885,171) or in combination with picibanil (U.S. Patent 4,401,653) has been shown to have antitumor activity. R. Martel et al. [Can. J. Physiol. Pharmacol. 55, 48 (1977)] disclosed that rapamycin is effective in the experimental allergic encephalomyelitis model, a model for multiple sclcrosis; in the adjuvant arthritis model, a model for rheumatoid arthritis; and effectively inhibited the formation of IgE-like antibodies. The immunosuppressive effects of rapamycin have been disclosed in FASEB 3, 3411 (1989). Cyclosporin A and FK-506, other macrocyclic molecules, also have been shown to be effective as immunosuppressive agents, therefore useful in preventing transplant rejection [FASEB 3, 3411 (1989); FASEB 3, 5256 (1989); R. Y. Calne et al.. Lancet 1183 (1978); and U.S. Patent 5,100,899]. Rapamycin has also been shown to be useful in preventing or treating systemic lupus erythematosus [U.S. Patent 5,078,999], pulmonary inflammation [U.S. Patent 5,080,899], insulin dependent diabetes mellitus [Fifth Int. Conf. Inflamm. Res. Assoc. 121 (Abstract), (1990)], smooth muscle cell proliferation and intimal thickening following vascular injury [Morris, R. J. Heart Lung Transplant 1 (pt. 2): 197 (1992)], adult T-cell leukemia/lymphoma [European Patent Application 525,960 A1], and ocular inflammation [European Patent Application 532,862 Al]. Mono- and diacylated derivatives of rapamycin (esterified at the 28 and 43 positions) have been shown to be useful as antifungal agents (U.S. Patent 4,316,885) and used to make water soluble aminoacyl prodrugs of rapamycin (U.S. Patent WO 95/28406 PCT/US95/04603 28 3 9 88 4,650,803). Recently, the numbering convention for rapamycin has been changed; therefore according to Chemical Abstracts nomenclature, the esters described above would be at the 31- and 42- positions. 5 DESCRIPTION OF THE INVENTION This invention provides derivatives of rapamycin which are useful as immunosuppressive, antiinflammatory, antifungal, antiproliferative, and antitumor agents having the structure wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 15 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR^R^fOR^, -CF3, -F, or -CO2R11, or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 20 -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)jOR1®, -CF3, -F, or 25 -CO2R11, or R8 and R9 may be taken together to form X or a cycloalkyl ring of WO 95/28406 PCI7US95/04603 28 3 9 8 8 -3- 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon 5 atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tctrahydropyranyl; RH is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; 10 X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; 15 b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted 20 cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salts are those derived from such inorganic cations such as sodium, potassium, and the like; and organic bases such as: mono-, di-, and trialkyl amines of 1-6 carbon atoms, per alkyl group and mono-, di-, and 25 trihydroxyalkyl amines of 1-6 carbon atoms per alkyl group, and the like. The terms alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, and alkynyl of 2-7 carbon atoms, include both straight chain as well as branched carbon chains. As the compounds of this invention can contain more than one -(CR3R4)fOR10 group, 30 R3, R4, f, and R10 can be the same or different. Similarly, when other generic substituent descriptions are repeated in the same structure, they can be the same or different. For a compound in which R1 contains R8 and R9 taken together to form X, where X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, the alkyl group of X 35 contains 1 carbon atom, and d = 0, R1 would have the following structure. WO 95/28406 PCT/US95/04603 28 3 9 0 d -4- -co(cr3r4)b ch3 ch3 Similarly, for a compound in which R1 contains R® and R9 taken together to form X, where X is 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, the cycloalkyl group of X contains 6 carbon atoms, and d = 0, R1 would have the following structure. For compounds containing X, preferred compounds include those in which the alkyl group of X, if present, is methyl and the cycloalkyl group of X, if present, is cyclohexyl. When R*0 is not hydrogen, alkyl, alkenyl, or alkynyl, it is intended that R1® is a group that can serve as an alcohol protecting group. Thus, these groups are intermediates of free hydroxylated compounds, as well as being biologically active in their own right. R1^ covers tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon 15 atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, and tetrahydropyranyl groups. Other alcohol protecting groups are known by one skilled in the art and are also considered part of this invention. 20 Of the compounds of this invention preferred members are those in which R2 is hydrogen; those in which R2 is hydrogen, b = 0, and d = 0; those in which R2 is hydrogen, b = 0, d = 0, and R8 and R9 are each, independently hydrogen, alkyl, or -(CR3R4)fOR10, or are taken together to form X. 25 Compounds of this invention having the ester group -CO(CR3R4)b(CR5R6)dCR7R8R9 at the 42- or 31,42-positions can be prepared by acylation of rapamycin using protected hydroxy and polyhydroxy acids, alkoxy or polyalkoxy carboxylic acids that have been activated, followed by removal of the 5 10 WO 95/28406 PCT/US95/04603 28 3 8 6 P > -5- alcohol protecting groups, if so desired. Several procedures for carboxylate activation are known in the an, but the preferred methods utilize carbodiimides, mixed anhydrides, or acid chlorides. For example, an appropriately substituted carboxylic acid can be activated as a mixed anhydride, with an acylating group such as 2,4,6-5 trichlorobenzoyl chloride. Treatment of rapamycin with the mixed anhydride under mildly basic condition provides the desired compounds. Alternatively, the acylation reaction can be accomplished with l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and dimethylaminopyridine. Mixtures of 42- and 31,42-esters can be separated by chromatography. 10 Accordingly, the invention also provides a process for preparing the rapamycin compounds of this invention. In particular this invention provides a process for preparing hydroxy esters of rapamycin including those of formula I as defined above which comprises: 15 a) acylating rapamycin or a functional derivative or analogue thereof with an acylating agent; or b) sequentially acylating rapamycin or a functional derivative or analogue thereof with two acylating agents; 20 said acylatiung agent(s) being selected from acids of formula HO-CO(CR3R4)b(CR5R6)dCR7R8R9 (u) or a reactive derivative thereof wherein R3-R9, b and d are as defined above providing that free hydroxy groups are protected, if desired protecting the 42-position of rapamycin or functional derivative with an appropriate protecting group and after the 25 reaction removing any protecting groups present as required. The reaction may be carried out in the presence of a coupling reagent, such as a suitably substituted carbodiimide coupling reagent. The above-mentioned compounds of this invention can also be prepared by acylation using reactive derivatives of the acid of formula II such as an anhydride, a mixed anhydride, or a acid halide such as the 30 chloride. The 31-ester-42-hydroxy compounds of this invention can be prepared by protecting the 42-alcohol of rapamycin with a protecting group, such as with a tert-butyl dimethylsilyl group, followed by esterification of the 31-position by the WO 95/28406 PCT/US95/04603 28 39 08 -6- procedures described above. The preparation of rapamycin 42-silyl ethers is described in U.S. Patent B1 5,120,842, which is hereby incorporated by reference. Removal of the protecting group provides the 31-esterified compounds. In the case of the tert-butyl dimethylsilyl protecting group, deprotecdon can be accomplished under mildly acidic 5 conditions, such as acetic acid / water / THF. The deprotection procedure is described in Example 15 of U.S. Patent 5,118,678, which is hereby incoiporated by reference. Having the 31-position esterified and the 42-position deprotected, the 42-position can be esterified using a different acylating agent than was reacted with the 31-alcohol, to give compounds having different esters at the 31- and 42- positions. 10 Alternatively, the 42-esterified compounds, prepared as described above, can be reacted with a different acylating agent to provide compounds having different esters at the 31-and 42-positions. This invention also covers analogous hydroxy esters of other rapamycins such 15 as, but not limited to, 29-demethoxyrapamycin, [U.S. Patent 4,375,464, 32-demethoxyrapamycin under C.A. nomenclature]; rapamycin derivatives in which the double bonds in the 1-, 3-, and/or 5-positions have been reduced [U.S. Patent 5,023,262]; 29-desmethylrapamycin [U.S. Patent 5,093,339, 32-desmethylrapamycin under C.A. nomenclature]; 7,29-bisdesmethylrapamycin [U.S. Patent 5,093,338, 20 7,32-desmethylrapamycin under C.A. nomenclature]; and 15-hydroxyrapamycin [U.S. Patent 5,102,876]. The disclosures in the above cited U.S. Patents are hereby incorporated by reference. Immunosuppressive activity for representative compounds of this invention was 25 evaluated in an in. vitro standard pharmacological test procedure to measure the inhibition of lymphocyte proliferation (LAF) and in two in vivo standard pharmacological test procedures. The pinch skin graft test procedure measures the immunosuppressive activity of the compound tested as well as the ability of the compound tested to inhibit or treat transplant rejection. The adjuvant arthritis standard 30 pharmacological test procedure, which measures the ability of the compound tested to inhibit immune mediated inflammation. The adjuvant arthritis test procedure is a standard pharmacological test procedure for rheumatoid arthritis. The procedures for these standard pharmacological test procedures are provided below. 35 The comitogen-induced thymocyte proliferation procedure (LAF) was used as an in vitro measure of the immunosuppressive effects of representative compounds. WO 95/28406 PCT/US95/04603 28 3 9 88 -7- Briefly, cells from the thymus of normal BALB/c mice are cultured for 72 hours with PHA and IL-1 and pulsed with tritiated thymidine during the last six hours. Cells are cultured with and without various concentrations of rapamycin, cyclosporin A, or test compound. Cells are harvested and incorporated radioactivity is determined. Inhibition 5 of lymphoproliferation is assessed as percent change in counts per minute from non-drug treated controls. For each compound evaluated, rapamycin was also evaluated for the purpose of comparison. An IC50 was obtainedfor each test compound as well as for rapamycin. When evaluated as a comparator for the representative compounds of this invention, rapamycin had an IC50 ranging from 0.6 -1.5 nM. The results obtained 10 are provided as an IC50 and as the percent inhibition of T-cell proliferation at 0.1 p.M. The results obtained for the representative compounds of this invention were also expressed as a ratio compared with rapamycin. A positive ratio indicates immunosuppressive activity. A ratio of greater than 1 indicates that the test compound inhibited thymocyte proliferation to a greater extent than rapamycin. Calculation of the 15 ratio is shown below. IC50 of Rapamycin IC50 of Test Compound 20 Representative compounds of this invention were also evaluated in an in vivo test procedure designed to determine the survival time of pinch skin graft from male BALB/c donors transplanted to male C3H(H-2K) recipients. The method is adapted from Billingham R.E. and Medawar P.B., J. Exp. Biol. 28:385-402, (1951). Briefly, 25 a pinch skin graft from the donor was grafted on the dorsum of the recipient as a allograft, and an isograft was used as control in the same region. The recipients were treated with either vaiying concentrations of test compounds intraperitoneally or orally. Rapamycin was used as a test control. Untreated recipients serve as rejection control. The graft was monitored daily and observations were recorded until the graft became 30 dry and formed a blackened scab. This was considered as the rejection day. The mean graft survival time (number of days ± S.D.) of the drug treatment group was compared with the control group. The following table shows the results that were obtained. Results are expressed as the mean survival time in days. Untreated (control) pinch skin grafts are usually rejected within 6-7 days. Compounds were tested using a dose of 4 35 mg/kg. WO 95/28406 PCT/US95/04603 28 3 9 8 -8- The adjuvant arthritis standard pharmacological test procedure measures the ability of test compounds to prevent immune mediated inflammation and inhibit or treat rheumatoid arthritis. The following briefly describes the test procedure used. A group of rats (male inbread Wistar Lewis rats) are pre-treated with the compound to be tested 5 (1 h prior to antigen) and then injected with Freud's Complete Adjuvant (FCA) in the right hind paw to induce arthritis. The rats are then orally dosed on a Monday, Wednesday, Friday schedule from day 0-14 for a total of 7 doses. Both hind paws are measured on days 16,23, and 30. The difference in paw volume (mL) from day 16 to day 0 is determined and a percent change from control is obtained. The left hind paw 10 (uninjected paw) inflammation is caused by T-cell mediated inflammation and is recorded in the above table (% change from control). The right hind paw inflammation, on the other hand, is caused by nonspecific inflammation. Compounds were tested at a dose of 5 mg/kg. The results are expressed as the percent change in the uninjected paw at day lfc versus control; the more negative the percent change, the more potent the 15 compound. Rapamycin provided between -70% and -90% change versus control, indicating that rapamycin treated rats had between 70-90% less immune induced inflammation than control rats. The results obtained in these standard pharmacological test procedures are 20 provided following the procedure for making the specific compounds that were tested. The results of these standard pharmacological test procedures demonstrate immunosuppressive activity both in vitro and i& vivo for the compounds of this invention. The results obtained in the LAF test procedure indicates suppression of 25 T-cell proliferation, thereby demonstrating the immunosuppressive activity of the compounds of this invention. Further demonstration of the utility of the compounds of this invention as immunosuppressive agents was shown by the results obtained in the skin graft and adjuvant arthritis standard pharmacological test procedures. Additionally, the results obtained in the skin graft test procedure further demonstrates 30 the ability of the compounds of this invention to treat or inhibit transplantation rejection. The results obtained in the adjuvant arthritis standard pharmacological test procedure further demonstrate the ability of the compounds of this invention to treat or inhibit rheumatoid arthritis. Based on the results of these standard pharmacological test procedures, the 35 compounds are useful in the treatment or inhibition of transplantation rejection such as kidney, heart, liver, lung, bone marrow, pancreas (islet cells), cornea, small bowel, WO 95/28406 PCT/US95/04603 283988 -9- and skin allografts, and heart valve xenografts; in the treatment or inhibition of autoimmune diseases such as lupus, rheumatoid arthritis, diabetes mellitus, myasthenia gravis, and multiple sclerosis; and diseases of inflammation such as psoriasis, dermatitis, eczema, seborrhea, inflammatory bowel disease, pulmonary inflammation 5 (including asthma, chronic obstructive pulmonary disease, emphysema, acute respiratory distress syndrome, bronchitis, and the like), and eye uveitis. Because of the activity profile obtained, the compounds of this invention also are considered to have antitumor, antifungal activities, and antiproliferative activities. The compounds of this invention therefore also useful in treating solid tumors, adult T-10 cell leukemia/lymphoma, fungal infections, and hyperproliferative vascular diseases such as restenosis and atherosclerosis. When used for restenosis, it is preferred that the compounds of this invention are used to treat restenosis that occurs following an angioplasty procedure. When used for this purpose, the compounds of this invention can be administered prior to the procedure, during the procedure, subsequent to the 15 procedure, or any combination of the above. When administered for the treatment or inhibition of the above disease states, the compounds of this invention can be administered to a mammal orally, parenterally, intranasally, intrabronchially, transdermally, topically, intravaginally, or rectally. 20 It is contemplated that when the compounds of this invention are used as an immunosuppressive or antiinflammatory agent, they can be administered in conjunction with one or more other immunoregulatory agents. Such other immunoregulatory agents include, but are not limited to azathioprine, corticosteroids, such as prednisone and methylprednisolone, cyclophosphamide, rapamycin, cyclosporin A, FK-506, 25 OKT-3, and ATG. By combining the compounds of this invention with such other drugs or agents for inducing immunosuppression or treating inflammatory conditions, the lesser amounts of each of the agents are required to achieve the desired effect. The basis for such combination therapy was established by Stepkowski whose results showed that the use of a combination of rapamycin and cyclosporin A at subtherapeutic 30 doses significantly prolonged heart allograft survival time. [Transplantation Proc. 23: 507 (1991)]. The compounds of this invention can be formulated neat or with a pharmaceutical carrier to a mammal in need thereof. The pharmaceutical carrier may be 35 solid or liquid. When formulated orally, it has been found that 0.01% Tween 80 in WO 95/28406 PCT/US95/04603 28 3 9 8 U -10- PHOSAL PG-50 (phospholipid concentrate with 1,2-propylene glycol, A. Nattermann & Cie. GmbH) provides an acceptable oral formulation. A solid canier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, 5 compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the canier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of 10 the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. Liquid carriers are used in preparing solution, suspensions, emulsions, 15 syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening 20 agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated 25 coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. 30 Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form. The compounds of this invention may be administered rectally in the form of a 35 conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of this invention may be formulated into an aqueous or WO 95/28406 PCT/US95/04603 28 3 9 8 8 -11 - partially aqueous solution, which can then be utilized in the form of an aerosol. The compounds of this invention may also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic 5 absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety 10 of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermiable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature. In addition, the compounds of this invention may be employed as a solution, 15 cream, or lotion by formulation with pharmaceutically acceptable vehicles containing 0.1 - 5 percent, preferably 2%, of active compound which may be administered to a fungally affected area. The dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular 20 subject being treated. Based on the results obtained in the standard pharmacological test procedures, projected daily dosages of active compound would be 0.1 |ig/kg -100 mg/kg, preferably between 0.001 - 25 mg/kg, and more preferably between 0.01 - 5 mg/kg. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect 25 under the circumstances is reached; precise dosages for oral, parenteral, nasal, or intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated. Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, tne composition is sub-divided in unit dose containing appropriate quantities of the active 30 ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. 35 The following examples illustrate the preparation and biological activities of representative compounds of this invention. WO 95/28406 PCT/US95/04603 28 3 9 88 Example 1 Rapamvcin 42-ester with (tetrahvdropvran-2-vloxvlacetic acid 2,4,6-Trichlorobenzoyl chloride (0.55 mL, 3.51 mmol) was added via syringe to a solution of the glycolic acid THP-ether (0.562 g, 3.51 mmol) and triethylamine 5 (0.49 mL, 3.51 mmol) in 10 mL THF at 0 °C under nitrogen. The mixture was stirred for 4 h at room temperature, and a white precipitate formed. The white precipitate was removed by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and warm water bath. The residue was dissolved in 30 mL benzene, then rapamycin (2.92 g, 3.19 mmol) and DMAP (0.429 g, 3.51 mmol) were added and the mixture 10 was stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with cold IN HC1 (aq), saturated NaHCC>3 (aq) and brine, dried over MgSC>4, filtered and concentrated to an oily yellow solid. Flash chromatography (2X with 65% EtOAc-hexane) afforded the title compound (1.114 g, 33%) as a white solid. 15 (-)FAB-MS m/z 1055.5 (M"), 590.3 (southern fragment), 463.2 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 8 4.60 (m, 1 H, C(42)H), 4.66 (m, 1 H), 4.14 (s, 2 H), 3.73 (m, 1 H), 3.42 (m, 1 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 169.2, 97.4, 63.5, 61.2, 29.7, 24.8, 18.8. 20 Example 2 Rapamvcin 42-ester with hvdroxvacetic acid p-Toluenesulfonic acid (10 mg) was added to a solution of the product of Example 1 (306 mg, 0.29 mmol) in 10 mL CH3OH at 0 °C. The solution was stirred 2 h at room temperature, then quenched with saturated NaHC03 solution. The aqueous 25 phase was extracted 3X with EtOAc and the combined organic phases were washed with brine, dried over MgS04, filtered and concentrated to a white solid. Purification by flash chromatography (2X with EtOAc) afforded the title compound (145 mg, 51%) as a white solid. 30 (-) FAB-MS m/z 971.3 (M"), 590 (southern fragment), 379.1 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 8 4.60 (m, 1 H, C(42)E), 3.98 (s, 2 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 172.1, 59.7. Results obtained in standard pharmacological test procedures: LAFIC50: 1.80 nM 35 LAF ratio: 0.83 Percent change in adjuvant arthritis versus control: -88% "WO 95/28406 PCT/US95/04603 28 3 9 8 8 13- Example 3 Rapamvcin 42-ester with 2.2-dimethvl-3-fteti-ahvdropvran-2-vloxv^propionic acid To a solution of the 2,2-dimethyl-3-hydroxypropionic acid THP-cther (0.319 g, 5 1.58 mmol) and triethylamine (0.22 mL, 1.58 mmol) in 5 mL dry THF at 0 °C under nitrogen was added 2,4,6-trichlorobenzoyl chloride (0.25 mL, 1.58 mmol) dropwise via syringe. The mixture was stirred 4.5 h at room temperature. The white precipitate was removed by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and a warm water bath. The residue was dissolved in 5 mL benzene, then 10 rapamycin (1.31 g, 1.43 mmol) and DMAP (0.193 g, 1.58 mmol) were added. The mixture was stirred overnight at room temperature, diluted with EtOAc, washed with IN HC1 (aq), saturated NaHC03 (aq), H2O and brine, dried over MgS04, filtered and concentrated to a yellow oily solid. Flash chromatography (IX with 60% EtOAc-hexane, IX with 55% EtOAc-hexane) afforded the title compound (0.356 g, 23%), as a 15 white solid. (-)FAB-MS m/z 1097.7 (M-), 590.4 (southern fragment), 505.3 (northern fragment). !H NMR (400 MHz, d-6 DMSO) 8 4.55 (m, 1 H, C(42)H), 4.55 (m, 1 H), 3.69 (m, 1 H), 3.60 (m, 2 H), 3.42 (m, 1 H), 1.13 (s, 3 H), 1.11 (s, 3 H). 20 13C NMR (100.6 MHz, d-6 DMSO) 8 175.0, 98.0, 73.8, 60.7, 42.6, 30.0, 24.9, 22.0, 21.6, 18.7. Results obtained in standard pharmacological test procedures: LAFIC50: 7.10 nM 25 LAF ratio: 0.34 Example 4 Rapamvcin 42-ester with 3-hvdroxv-2.2-dimethvlpropionic acid p-Toluenesulfonic acid (10 mg) was added to a solution of the product of 30 Example 3 (250 mg, 0.23 mmol) in 10 mL CH3OH a* 0 °C. The solution was stirred 2 hours at room temperature, then pyenched with saturated NaHC03 solution. The aqueous phase was extracted 3X v*ith EtOAc and ihe combined organic phases were washed with brine, dried over MgS04, filtered and concentrated to a white solid. Purification by flash chromatography (2X with 75% EtOAc-hexane) afforded the title 35 compound (103 mg, 45%) as a white solid. WO 95/28406 PCT/US95/04603 Z8 3 9 8 8 (-) FAB-MS mlz 1013.3 (M"), 590.2 (southern fragment), 421.1 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 5 4.48 (m, 1 H, C(42)H), 3.39 (d, 2 H), 1.06 (s, 6 H). 13c NMR (100.6 MHz, d-6 DMSO) 5 175.5,68.0,44.1, 21.7. 5 Results obtained in standard pharmacological test procedures: LAF IC50: 0.80 nM LAF ratio: 1.25 Skin graft survival time: 10.7 ± 0.5 days 10 Examples 5 and 6 Rapamvcin 42-ester with 2.2-dimethviri.31dioxalane-4-caTboxvlic acid (Ex. 5) Rapamvcin 31.42-diester with 2.2-dimethvin.31dioxalane-4-carboxvlic acid (Ex. 6) 2,4,6-Trichlorobcnzoyl chloride (0.56 mL, 3.61 mmol) was added via syringe 15 to a solution of the 2,3-dihydroxypropionic acid isopropylidene ketal (0.527 g, 3.61 mmol) and triethylamine (0.50 mL, 3.61 mmol) in 10 mL THF at 0 °C under nitrogen. The mixture was stirred 4 h at room temperature. The white precipitate was removed by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and warm water bath. The residue was dissolved in 15 mL benzene and rapamycin (3.00 20 g, 3.28 mmol), then DMAP (0.441 g, 3.61 mmol) were added and the mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with cold IN HC1 (aq), saturate NaHC03 (aq) and brine, dried over MgS04, filtered and concentrated to a yellow foam. Flash chromatography on silica gel (gradient elution: 50-60-75-100% EtOAc-hexane, 4X with 65% EtOAc-hexane) afforded the title 25 compounds. The less polar 31,42-diester (0.415 g) eluted first and the more polar 42-monoester (0.601 g, 16%) eluted second, and were isolated as white solids. Example 5 (-)FAB-MS m/z 1041.4 (M-), 59C.3 (southern fragment), 449.2 (northern fragment). 30 1H NMR (400 MHz, d-6 DMSO) 5 4.6 (m, 1 H, C(42)H), 4.6 (m, 1 H), 4.20 (dd, 1 H), 3.96 (m, 1 H), 1.36 (s, 3 H), 1.30 (s, 3 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 170.5, 110.2, 73.4, 66.6, 25.7, 25.4. WO 95/28406 - 15 Example 6 (-)FAB-MS mJz 1169.6 (M*). NMR (400 MHz, d-6 DMSO) 5 5.3 (m, 1 H, C(31)H), 4.6 (m, 1 H, C(42)H), 4.6 (m, 2 H), 4.19 (t, 1 H), 4.13 (t, 1 H), 3.9 (m, 2 H), 1.36 (s, 3 H), 1.33 (s, 3 H), 5 1.30 (s, 3 H), 1.28 (s, 3 H). 13C NMR (100.6 MHz, d-6 DMSO) 5 170.5, 169.2, 110.3, 110.2, 73.4, 66.6, 66.5, 25.8, 25.7, 25.4, 25.1. Results obtained in standard pharmacological test procedures: 10 Example 5 LAFIC50: 1.20 nM LAF ratio: 0.74 Exaniple 6 15 LAFIC50: 1.30 nM LAF ratio: 0.5 Example 7 Rapamvcin 42-ester with 2.3-dihvdroxvpropionic acid 20 A solution of the product of Example 5 (351 mg, 0.34 mmol) in 10 mL THF and 10 mL IN HC1 was stirred at room temperature for 6 h. The mixture was diluted with EtOAc, washed with saturated NaHC03 solution and brine, dried over MgS04, filtered and concentrated to an oil. Flash chromatography (IX with EtOAc, IX with 10% MeOH-CH2Cl2» IX with 5% MeOH-EtOAc) afforded the title compound (78 mg, 25 23%) as a white solid. (-)FAB-MS m/z 1001.2 (M"), 590.2 (southern fragment), 409.1 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 5 4.5 (m, 1 H, C(42)H), 3.60 (m, 1 H), 3.45 (m, 2 H). 30 Results obtained in standard pharmacological test procedures: LAFIC50: 1.4 nM LAF ratio: 0.40 PCT/US95/04603 2839 8 WO 95/28406 PCT/US95/04603 2839 8 - 16-Example 8 Rapamvcin 42-ester with 2.2-dimethviri.31dioxanc-5-carboxvlic acid 2,4,6-Trichlorobenzoyl chloride (0.98 mL, 6.27 mmol) was added via syringe to a solution of the 2-(hydroxymethyl)-3-hydroxypropionic acid isopropylidene ketal 5 (1.000 g, 6.24 mmol) and triethylamine (0.90 mL, 6.46 mmol) in 20 mL THF at 0 °C under nitrogen. The mixture was stirred for 4 h at room temperature, and a white precipitate formed. The white precipitate was removed by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and warm water bath. The residue was dissolved in 20 mL benzene, then rapamycin (5.70 g, 6.24 mmol) and DMAP 10 (0.762 g, 6.24 mmol) were added and the mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with H2O and brine, dried over MgS04, filtered and concentrated to a yellow solid. Flash chromatography (75% EtOAc-hexane) afforded the title compound (4.17 g, 63%) as a white solid. 15 (-)FAB-MS m/z 1055.8 (M-), 590.5 (southern fragment), 463.4 (northern fragment). !H NMR (400 MHz, d-6 DMSO) 8 4.55 (m, 1 H, C(42)H), 3.95 (m, 4 H), 1.30 (s, 6 H). 13c NMR (100.6 MHz, d-6 DMSO) 8 170.1, 97.4, 59.5, 24.8, 22.5. 20 Results obtained in standard pharmacological test procedures: LAFIC50: 0.76 nM LAF ratio: 0.45 Example 9 25 Rapamvcin 42-ester with 3-hvdroxv-2-hvdroxvmethvlpropionic acid A solution of the product of Example 8 (3.30 g, 3.12 mmol) in 50 mL THF and 25 mL IN HC1 was stirred 2 h at room temperature. The solution was diluted with saturated NaHC03 solution and extracted with EtOAc (3X). The combined organic phases were washed with saturated NaCl (aq), dried over MgS04, filtered and 30 concentrated to a yellow foam. Purification by flash chromatography (IX with EtOAc; 2X with 5% EtOH-EtOAc) afforded the title compound (1.68 g, 53 %) as a white solid. (-)FAB-MS m/z 1015.5 (M*), 590.3 (southern fragment), 423.3 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 8 4.6 (br s, 2 H), 4.55 (m, 1 H , C(42)H), 3.55 (m, 35 4 H), 2.57-2.53 (m, 1 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 172.2, 59.3, 51.5. WO 95/28406 PCT/US95/04603 28 39 8 8 - 17 Results obtained in standard pharmacological test procedures: LAFIC50: 0.84 nM LAF ratio: 0.57 5 Example 10 Rapamvcin 42-ester with 2.2.5-trimethviri.31dioxane-5-carboxvlic acid To a solution of the 2,2-bis(hydroxymethyl)propionic acid isopropylidene ketal (1.041 g, 5.98 mmol) (prepared according to the procedure of Bruice, J. Am. Chem. 10 Soc. 89: 3568 (1967)) and triethylamine (0.83 mL, 5.98 mmol) in 20 mL anhydrous THF at 0 °C under nitrogen was added 2, 4, 6-trichlorobenzoyl chloride (0.93 mL, 5.98 mmol) and the resultant white suspension was stirred 5 h at room temperature. The precipitate was removed by vacuum filtration, rinsing the flask and filter cake with an additional 10 mL dry THF. The filtrate was concentrated by rotary evaporation to a 15 white solid. The residue was dissolved in 20 mL dry benzene, then rapamycin (5.47 g, 5.98 mmol) and DMAP (0.731 g, 5.98 mmol) were added. After stilting overnight at room temperature, the mixture was diluted with EtOAc, washed with H2O and saturated NaCl (aq), dried over MgS04, filtered and evaporated to a yellow oil. Rash chromatography (5X with 60% EtOAc-hexane) afforded the title compound (2.2 g, 34 20 %) as a white solid. (-)FAB-MS mJz 1069.5 (M"), 590.3 (southern fragment), 477.2 (northern fragment). *H NMR (400 MHz, d-6 DMSO) 6 4.57 (rn, 1 H, C(42)K), 4.02 (d, 2 H), 3.60 (d, 2 H), 1.34 (s, 3 H), 1.24 (s, 3 H), 1.06 (s, 3 H). 13c NMR (100.6 MHz, d-6 DMSO) 8 173.2, 99.0, 65.0, 22.2, 18.1. 25 Results obtained in standard pharmacological test procedures: LAFIC50: 4.90 nM LAF ratio: 0.41 Skin graft survival time: 11.0 ± 1.3 days 30 Example 11 Rapamvcin 42-ester with 2.2-bis-fhvdroxvmethvnproDionic acid A solution of the product of Example 10 (2.8 g, 2.65 mmol) in 50 mL THF and 25 mL IN HC1 was stirred at room temperature for 4 h. The mixture was diluted with water and extracted three times with EtOAc. The combined organic phases were 35 washed with saturated NaHC03 solution, saturated NaCl solution, dried over MgS04, WO 95/28406 PCT/US95/04603 28 39 88 filtered and evaporated to a yellow oily solid. Purification by flash chromatography (3X with EtOAc) afforded the title compound (1.6 g, 59 %). (-)FAB-MS m/z 1029.6 (M*), 590.4 (southern fragment), 437.3 (northern fragn snt). NMR (400 MHz, d-6 DMSO) 8 4.5 (m, 1 H, C(42)H), 3.45 (s, 4 H), 1.04 (s, 5 3 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 174.2, 63.7, 63.6, 49.9, 16.8. Results obtained in standard pharmacological test procedures: LAF IC50: 0.80 and 1.80 nM LAF ratio: 1.00 and 0.44 10 Skin graft survival time: 11.4 ± 1.5 and 12.0 ±1.1 days Percent change in adjuvant arthritis versus control: -88% Example 12 Rapamvcin 42-ester with 2.2-dimethvl-5-(2-trimethvlsilanvlethoxvmethvl)n.31-15 dioxane-5-carboxvlic acid 2,4,6-Trichlorobenzoyl chloride (0.14 mL, 0.86 mmol) was added via syringe to a solution of the 2,2-bis(hydroxymethyl)-2-(2-trimethylsilylethoxy)propionic acid isopropylidene ketal (0.250 g, 0.86 mmol) and triethylamine (0.12 mL, 0.86 mmol) in 2 mL THF at 0 °C under nitrogen. The mixture was stirred for 4 h at room 20 temperature, and a white precipitate formed. The white precipitate was removed by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and warm water bath. The residue was dissolved in 2 mL benzene, then rapamycin (0.786 g, 0.86 mmol) and DMAP (0.105 g, 0.86 mmol) were added and the mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with 25 H2O and brine, dried over MgS04, filtered and concentrated to a yellow solid. Flash chromatography (gradient elution: 40-60-80-100% EtOAc-hexane) afforded the title compound (0.559 g, 54%) as a white solid. (-)FAB-MS m/z 1185.2 (M-), 590.1 (southern fragment), 593 (northern fragment). 1H NMR (400 MHz, d-6 DMSO) 8 4.55 (m, 1 H, C(42)H), 3.73 (m, 4 H), 3.57 (s, 30 2 H), 3.43 (t, 2 H), 1.29 (s, 6 H), 0.79 (t, 2 H), -0.04 (s, 9 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 171.1, 97.7, 70.2, 68.1, 61.3, 46.0, 24.6, 22.1, 14.6, -1.3. Results obtained in standard pharmacological test procedures: LAFIC50: 7.20 nM 35 LAF ratio: 0.05 </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 95/28406 PCT/US95/04603 28 3 9 8 8 -19- Examples 13 and 14 Ranamvcin 42-ester with 3-methvl-1.5-dioxa-spiror5.51undecane 3-carboxvlic acid (Ex, 13) Rapamvcin 31.42-diester with 3-methvl-l .5-dioxa-spiror5.51nndecane 3-carboxvlic 5 acid (Ex. 14^ 2,4,6-Trichlorobenzoyl chloride (0.16 mL, 1.0 mmol) was added via syringe to a solution of the 2,3-dihydroxypropionic acid cyclohexylidene ketal (0.214 g, 1.0 mmol) and triethylamine (0.14 mL, 1.0 mmol) in 2.5 mL THF at 0 °C under nitrogen. The mixture was stirred 4 h at room temperature. The white precipitate was removed 10 by vacuum filtration and the filtrate was concentrated with a stream of nitrogen and warm water bath. The residue was dissolved in 3 mL benzene and rapamycin (0.457 g, 0.5 mmol), then DMAP (0.061 g, 0.5 mmol) were added and the mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc, washed with cold IN HC1 (aq), saturated NaHC03 (aq) and brine, dried over MgS04, filtered 15 and concentrated to a yellow foam. Flash chromatography on silica gel (45-50% EtOAc-hexane) afforded the title compounds. The 31,42-diester (0.168 g, 26%) eluted first and the more polar 42-monoester (0.301 g, 52%) eluted second, and the products were isolated as white solids. Example 13 20 (-)FAB-MS m/z 1109.5 (M-), 590.3 (southern fragment), 517.3 (northern fragment). !H NMR (400 MHz, d-6 DMSO) 8 4.55 (m, 1 H, C(42)K), 3.61 (t, 4 H), 1.04 (s, 3 H). !3C NMR (100.6 MHz, d-6 DMSO) 8 173.3, 97.2, 64.2. Example 14 25 (-)FAB-MS m/z 1305.6 (M*). !H NMR (400 MHz, d-6 DMSO) 5 5.25 (m, 1 H, C(31)H), 4.55 (m, 1 H, C(42)H), 3.64-3.54 (m, 8 H), 1.05 (s, 3 H), 0.97 (s, 3 H). 13C NMR (100.6 MHz, d-6 DMSO) 8 173.2, 172.1, 97.3, 97.2, 64.3, 64.2, 63.9. Results obtained in standard pharmacological test procedures: 30 Example 13 LAFIC50: 0.6 nM LAF ratio: 2.00 Example 14 LAF: inhibited T-cell proliferation by 43% at 0.1 |iM WO 95/28406 PCT/US95/04603 -20-CLATMS 28 3 & v What is claimed is: 1. A compound of the structure (I) 5 wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 10 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R1 or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-15 7 carbon atoms, -(CR3R4)fOR*0, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R11, or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 20 -(CR3R4)fOR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silylethyl, friphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, WO 95/28406 PCT/US95/04603 28 3 9 8 8 -21 - tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or letrahydropyranyl; R11 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; 5 X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; 10 b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted 15 cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R2 is hydrogen or a pharmaceutically acceptable salt thereof. 20
3. The compound of claim 2, wherein b = 0 and d = 0 or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3, wherein R8 and R9 are each, independently hydrogen, alkyl, or -(CR3R4)fOR10, or are taken together to form X or a 25 pharmaceutically acceptable salt thereof.
5. The compound of claim 1 which is rapamycin 42-ester with (tetrahydropyran-2-yloxy)acetic acid or a pharmaceutically acceptable salt thereof. 30
6. The compound of claim 1 which is rapamycin 42-ester with hydroxyacetic acid or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 which is rapamycin 42-estcr with 2,2-dimethyl-3- (tetrahydropyran-2-yloxy)propionic acid or a pharmaceutically acceptable salt thereof. WO 95/28406 PCT/US95/04603 283988 -22-
8. The compound of claim 1 which is rapamycin 42-ester with 3-hydroxy-2,2-dimethylpropionic acid or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 which is rapamycin 42-ester with 2,2-5 dimethyl[ 1,3]dioxalane-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 which is rapamycin 31,42-diester with 2,2-dimethyl[l,3]dioxalane-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 10
11. The compound of claim 1 which is rapamycin 42-ester with 2,3-dihydroxypropionic acid or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 which is rapamycin 42-ester with 2,2-dimethyl[l,3]dioxane-5-carboxylic acid or a pharmaceutically acceptable salt thereof. 15
13. The compound of claim 1 which is rapamycin 42-ester with 3-hydroxy-2-hydroxymethylpropionic acid or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 which is rapamycin 42-ester with 2,2,5-20 trimethyl[ 1,3]dioxane-5-carboxylic acid or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 which is rapamycin 42-ester with 2,2-bis-(hydroxymethyl)propionic acid or a pharmaceutically acceptable salt thereof. 25
16. The compound of claim 1 which is rapamycin 42-ester with 2,2-dimethyl-5-(2-trimethylsilanylethoxymethyl)[l,3]-dioxane-5-carboxylic acid or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 which is rapamycin 42-ester with 3-methyl-l,5-30 dioxa-spiro[5.5]undecane 3-carboxylic acid or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 which is rapamycin 31,42-diester with 3-methyl-l,5-dioxa-spiro[5.5]undecane 3-carboxylic acid or a pharmaceutically acceptable salt 35 thereof. WO 95/28406 PCT/US95/04603 - 23 - %f
19. The use, in the manufacture of a new medicament, of an antirejection effective amount of a compound of the structure. wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, a'Jcenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fORl0, -CF3, -F, or -CO2R11, or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, -(CR3R4)fORiO, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR1^, -CF3, -F, or -CCHR1 or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, fl (I) WO 95/28406 PCT/US95/04603 -24- ?83 § tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tctrahydropyranyl; Rl l is hydrogen, alkyl of 1-6 carbon aioms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; X is 5-(2,2-di*{alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 arid R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof, for treating transplantation rejection or graft vs host disease in a mammal in need thereof.
20. The use, in the manufacture of a new medicament, of an antifungal effective amount of a compound of the structure wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; OR1 (I) WO 95/28-406 PCI7US93/04603 3 98 R5 and are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR^R4)fOR1^, -CF3, -F, or -CO2R11, or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 5 -(CR3R4){OR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, -(CR3R4)(OR10, -CFj, -F, or -CO^R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or 10 -CO2R1or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fORt0; RlO is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon 15 atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethy] of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tetrahydropyranyl; R11 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; 20 X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))(l,3]dioxanvl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; 25 b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either Rl or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted 30 cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof , for treating a fungal infection in a mammal in need thereof. WO 95/28406 PCT/US95/04603
21. The use, in the manufacture of a medicament, of an antiarthritis effective amounfo compound of the structure. 5 wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; RJ and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyi, or -F; R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 10 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R1 or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR'°; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-15 7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R1 or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 20 -(CR3R4)fOR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silvlethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, WO 95/28406 PCT7US95/04603 -27- lri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tetrahydropyranyi; Rll is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, orphenylalkyl of 7-10 carbon atoms; X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[ l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; b = 0-6; d = 0-6; and f = 0-6 with the prrviso that R1 and R2 are both not hydrogen and further provided that either Rl or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof , for treating rheumatoid arthritis in a mammal in need thereof.
22. The use, in the manufacture of a medicament, of an antiproliferative effective amount of a compound of the structure wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9 . R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of (I) 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; WO 95/28406 PCPgJS95/04603 -28- R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -{CR3R4)fOR10, -CF3, -F, or -COoR1or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 5 -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, -(CR3R4)fOR10, -CF3, -F. or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)f0R10, -CF3, -F, or 10 -CO2R1 ^ or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; RlO is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon 15 atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tetrahydropyranyl; R11 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; 20 X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-{2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2.2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cvcloalkyl of 3-8 carbon atoms))[l,3]dioxaJanyl; 25 b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 arc both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted 30 cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof, for treating restenosis in a mammal in need thereof. WO 95/28406 PCT/US9 *** 0 Q -29-
23. The use, in the manufacture of a medicament, of an antiinflammatory effective amount of a compound of the structure (I) 5 wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, jndependendy, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or-F; R5 and R6 are each, independendy, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 10 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or -CO2R1or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-15 7 carbon atoms, -(CR^fOR™, -CF3, -F, or -CO2R11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR1^, -CF3, -F, or -CO2R1or R8 and R9 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 20 -(CR3R4)fOR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or tetrahydiopyranyl; R11 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, orphenylalkyl of 7-10 carbon atoms; X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyl, 5-(2,-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))(l,3]-dioxanyl, 4-(2-spiro(cycloaikyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms)) [l,31dioxalanyl; b = 0-6; d = 0-6; and f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)fOR10 substituted cycloalkyl of 3-8 carbon atoms group, or a pharmaceurically acceptable salt thereof, for treating pulmonary inflammation in a mammal in need thereof.
24. A pharmaceutical composition which comprises a compound of the structure wherein R1 and R2 are each, independently, hydrogen or -CO(CR3R4)b(CR5R6)dCR7R8R9; R3 and R4 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, trifluoromethyl, or -F; R5 and R6 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or OR (I) WO 95/28406 PCT/US95/04603 28 3 9 -31 - -CO2R11, or R5 and R6 may be taken together to form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with -(CR3R4)fOR10; R7 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-5 7 carbon atoms, -(CR3R4)fOR10, -CF3, -F, or-COj^11; R8 and R9 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, -(CR3R4)fORlO, -CF3, -F, or -CO2R11, or R8 and R^ may be taken together tu form X or a cycloalkyl ring of 3-8 carbon atoms that is optionally mono-, di-, or tri-substituted with 10 -(CR3R4){OR10; R10 is hydrogen, alkyl of 1-6 carbon atoms, alkenyi of 2-7 carbon atoms, alkynyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silyl, tri-(alkyl of 1-6 carbon atoms)silylethyl, triphenylmethyl, benzyl, alkoxymethyl of 2-7 carbon atoms, tri-(alkyl of 1-6 carbon atoms)silylethoxymethyl, chloroethyl, or 15 tetrahydropyranyl; R11 is hydrogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, alkynyl of 2- 7 carbon atoms, or phenylalkyl of 7-10 carbon atoms; X is 5-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]dioxanyI, 5-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxanyl, 4-(2,2-di-(alkyl of 1-6 carbon atoms))[l,3]-20 dioxanyl, 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[ 1,3]dioxanyl, 4-(2,2-di- (alkyl of 1-6 carbon atoms))[l,3]dioxalanyl, or 4-(2-spiro(cycloalkyl of 3-8 carbon atoms))[l,3]dioxalanyl; b = 0-6; d = 0-6; and 25 f = 0-6 with the proviso that R1 and R2 are both not hydrogen and further provided that either R1 or R2 contains at least one -(CR3R4)fOR10, X, or -(CR3R4)jOR10 substituted cycloalkyl of 3-8 carbon atoms group, or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier. 30
25. A process for preparing hydroxy esters of rapamycin including those of formula I as defined in Claim 1 which comprises: a) acylating rapamycin or a functional derivative or analogue thereof with an acylating agent; 35 or WO 95/28406 PCT/US95/04603 283988 -32- b) sequentially acylating rapamycin or a functional derivative or analogue thereof with two acylating agents; said acylatiung agent(s) being selected from acids of formula HO-CO(CR3R4)b(CR5R6)dCR7R8R9 (U) 5 or a reactive derivative thereof wherein R3-R9, b and d are as defined in Claim 1 providing that free hydroxy groups are protected, if desired protecting the 42-position of rapamycin or functional derivative with an appropriate protecting group and after the reaction removing any protecting groups present as required. of </div>